![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOXICOLOGY
Departments of Pharmacology and Toxicology (K.E.M., W.P., J.C., Y.J.K.) and Medicine (W.F., L.Z., J.B.K., Y.J.K.), University of Louisville School of Medicine, Louisville, Kentucky
Previous studies using a cardiac-specific metallothionein (MT)-overexpressing transgenic (MT-TG) mouse model have demonstrated that MT protects from doxorubicin (DOX)-induced oxidative heart injury. The molecular mechanisms that underlie this cardioprotection, however, have yet to be defined. In the present study, we tested the hypothesis that MT overexpression activates cytoprotective mechanisms, leading to cardiac protection from DOX toxicity. MT-TG mice and nontransgenic wild-type (WT) controls were treated i.p. with DOX at a single dose of 20 mg/kg and sacrificed on the third day after the treatment. An expression proteomic analysis involving two-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry was used to identify MT-induced changes in cytoprotection-related proteins. We identified 18 proteins that were modified by DOX treatment in the heart. These proteins included those involved in cellular antioxidant defense, enzymes of the mitochondrial electron transport chain, enzymes involved in 
-oxidation of fatty acids and glycolysis, and proteins involved in regulation of cardiac muscle contraction. However, the most dominant modification by MT is the cytochrome c oxidase subunit Va (CCO-Va). In response to DOX treatment, a specific isoform of CCO-Va was enhanced in the MT-TG but not in the WT mouse hearts. Because CCO-Va is a critical component in the mitochondrial electron transport chain, the results suggest that the cardioprotective effect of MT may be related to an increased expression or a differential modification of CCO-Va.
Address correspondence to: Dr. Y. James Kang, Department of Medicine, University of Louisville School of Medicine, 511 South Floyd Street, MDR 530, Louisville, KY 40202. E-mail: yjkang01{at}louisville.edu
This article has been cited by other articles:
|
|
 |
|
  Q. Yu, T. Nguyen, M. Ogbi, R. W. Caldwell, and J. A. Johnson Differential loss of cytochrome-c oxidase subunits in ischemia-reperfusion injury: exacerbation of COI subunit loss by PKC-{varepsilon} inhibition Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2637 - H2645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Merten, Y. Jiang, and Y. J. Kang Zinc Inhibits Doxorubicin-Activated Calcineurin Signal Transduction Pathway in H9c2 Embryonic Rat Cardiac Cells Experimental Biology and Medicine, May 1, 2007; 232(5): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Poulsen, R. Borup, N. Borregaard, F. C. Nielsen, M. B. Moller, and E. Ralfkiaer Prognostic significance of metallothionein in B-cell lymphomas Blood, November 15, 2006; 108(10): 3514 - 3519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Merten, Y. Jiang, W. Feng, and Y. J. Kang Calcineurin Activation Is Not Necessary for Doxorubicin-Induced Hypertrophy in H9c2 Embryonic Rat Cardiac Cells: Involvement of the Phosphoinositide 3-Kinase-Akt Pathway J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 934 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Kang Metallothionein redox cycle and function. Experimental Biology and Medicine, October 1, 2006; 231(9): 1459 - 1467. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
